Please login to the form below

Not currently logged in
Email:
Password:

GSK corruption claims extend to Jordan and Lebanon

Follows bribery allegations in Poland, China and Iraq

GSK - logo on building 

GlaxoSmithKline's investigation into bribery and corruption among its employees has now extended into Lebanon and Jordan.

GSK confirmed yesterday that it was looking into the activity of a "small number of individuals" in these countries, just days after bribery allegations emerged in Poland. The company is also facing probes into its conduct in Iraq and China.

"We started investigating using internal and external teams as soon as we became aware of these claims," said GSK in a statement. "These investigations have not yet concluded."

As with the Poland incident the allegations have been made by a whistleblower who claims GSK sales staff tried to encourage doctors in Jordan and Lebanon to prescribe medicines - including GSK's pneumococcal vaccine Synflorix - by providing free samples that they could sell on at a $70-per-vial profit.

The whistleblower also said GSK allowed doctors to bring family members on paid business trips and in some instances swap business-class airline tickets for economy, with the doctor pocketing the difference, according to a Wall Street Journal report. It is further alleged that GSK staff paid certain doctors to attend lecture and presentations that may not have taken place.

"GSK welcomes and respects people speaking up where they have concerns and we have a number of channels internally to enable them to do this, including hotlines and online portals," said the company.

It also maintained that the number of violations of sales and marketing practices are publicly disclosed and in line with other companies in the pharma sector. Last year, GSK recorded 161 violations relating to breaches of our sales and marketing polices, resulting in 48 dismissals and 113 written warnings.

"We are confident in our processes and controls and that we do not have a systemic issue with unethical behaviour in GSK," said the firm, which is presumably worried the continuing newsflow in this area could prompt investigations by financial regulators in the US and UK, which have specific legislation banning the payment of inducements to foreign officials to obtain business.

GSK has already introduced sweeping changes to its sales and marketing policies in recent months, including removing sales targets for reps and shifting to in-house doctors and scientists rather than external speakers.

Article by
Phil Taylor

17th April 2014

From: Sales, Marketing, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Gem Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

How ethical is your brand plan? Introducing the hEQ.
Assess your brand plan’s Healthcare Ethics Quotient and see how these questions can give your brand plan a new perspective and engage your internal teams and external customers....
solution_options.png
Why e-detailing must give options to healthcare professionals
We know, we know. You want to talk about your treatment right away, but this really is an essential step that will make your e-detailing even more credible....
Is obesity really a problem in Brazil?
Obesity is on the rise in low- and middle-income countries, particularly in urban settings...